BOT - Anything but charting, page-4791

I think multiple dollars in a few years time when SB has funded further successful Phase 3 trials in anti-microbial, acne and rosacea and one or more have FDA approval. All 4 are winners - it's just going to take time. But to me, anti-microbial could be a game changer with it's shortened approval process and exclusive regulatory protection. Acne Ph 3 will be huge too, IMO.

Maybe in the short to medium term SB will see us get to 30-50c, but if we do only sell the same number of scripts as Japan already do, that's income circa $80m. $80m / 1.3b shares x PE15 = $0.92. I think that's hopeful, but the US is 3 x the size of Japan and they do sell that number of scripts in Japan already.